Business Context and Reporting Period
Company: RF Acquisition Corp II (RFAI)
Reporting Period: Quarter ended September 30, 2025 (Form 10-Q)
Business Overview: A Cayman Islands exempted company formed as a Special Purpose Acquisition Company (SPAC) to effect a business combination with a target in the deep technology sector (AI, quantum computing, biotechnology) in Asia. The Company has not commenced operations and generates no operating revenue.
Key Event: On October 2, 2025, the Company entered into a Business Combination Agreement with Nanyang Biologics Pte. Ltd. ("Nanyang").
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | Q3 2024 (3 Months) |
|---|---|---|---|
| Operating Costs | $229,662 | $624,629 | $89,990 |
| Interest Income (Trust Account) | $1,286,531 | $3,778,478 | $1,512,941 |
| Net Income | $1,056,869 | $3,153,849 | $1,422,951 |
| Cash (Outside Trust) | $562,225 | $562,225 | $986,256 |
| Cash in Trust Account | $122,872,409 | $122,872,409 | $119,093,931 |
| Working Capital | $64,578 | $64,578 | N/A |
| Deferred Underwriting Fee | $4,025,000 | $4,025,000 | $4,025,000 |
Material Changes vs. Prior Period
- Operating Costs: Increased significantly to $229,662 in Q3 2025 compared to $89,990 in Q3 2024, reflecting higher expenses related to the pursuit of a business combination.
- Trust Account Balance: Increased to $122.87 million from $119.09 million at year-end 2024, driven by interest earnings of $3.78 million YTD.
- Cash Position: Operating cash outside the trust decreased to $562,225 from $958,786 at December 31, 2024, due to net cash used in operating activities of $396,561 for the nine months ended September 30, 2025.
- Liabilities: Current liabilities increased to $526,764 from $295,200, primarily due to accrued expenses and increased amounts due to the Sponsor.
Outlook, Risks, and Management Commentary
- Business Combination: The Company has signed an agreement to merge with Nanyang Biologics. The transaction involves a merger with NYB Holdings Limited (PubCo) and an amalgamation with Nanyang.
- Extension Proposal: The Company filed a proxy statement for a shareholder meeting on November 10, 2025, to extend the deadline to consummate a business combination from November 15, 2025, to August 15, 2026. This requires depositing $0.03 per share into the Trust Account for each one-month extension.
- Going Concern: Management has determined that conditions raise substantial doubt about the Company's ability to continue as a going concern for one year following the issuance of the financial statements, as the Company relies on completing a business combination or obtaining additional financing.
- Risks: Geopolitical instability (Russia-Ukraine, Israel-Hamas conflicts) may impact global markets and the ability to complete a transaction. There is no assurance the business combination will be successful.
- Controls and Procedures: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025.
Investor Verification Checklist
- Extension Vote: Verify the outcome of the November 10, 2025 shareholder vote regarding the extension of the combination period to August 2026.
- Transaction Status: Monitor the progress of the Business Combination Agreement with Nanyang Biologics and any regulatory approvals required.
- Liquidity: Assess the sufficiency of the $562,225 cash balance outside the trust to fund operations until the transaction closes or liquidation occurs.
- Redemption Rights: Review the terms of the extension proposal regarding the $0.03 per share deposit requirement and its impact on the trust value per share.
- Internal Controls: Investigate the specific material weaknesses that led to the conclusion that disclosure controls were ineffective.